Fast Titration in the Treatment of Schizophrenia, Taiwan

NCT ID: NCT00304473

Last Updated: 2009-03-25

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2004-08-31
• Study Completion Date: 2006-04-30

Brief Summary

Assess the efficacy of a fast titration of quetiapine to the current titration approved by the regulatory authorities.

PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

Conditions

Schizophrenia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

Quetiapine fumarate

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Signed informed consent, at least 18 years old, inpatients with relapse Schizophrenia all subtypes, and with a CGI (Clinical Global Impression) score >=4.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

AstraZeneca

INDUSTRY

Sponsor Role: lead

Principal Investigators

AstraZeneca Taiwan Medical Director, MD

Role: STUDY_DIRECTOR

AstraZeneca

Locations

Research Site

Taoyuan District, , Taiwan

Countries

Taiwan

Other Identifiers

D1449C00001

Identifier Type: -

Identifier Source: org_study_id